Tune Therapeutics
Dr. Heidi Zhang is the Executive Vice President and Head of Technical Operations at Tune Therapeutics.
A seasoned scientific executive who has led global teams across a range of biotech and pharma companies, including Juno Therapeutics, Genentech, Novartis, and Amgen. Prior to Tune, Heidi was the Vice President of Cell Therapy Product & Analytical Development at Bristol Myers-Squibb.
Her many accomplishments in science and leadership include commercial launches of numerous life-saving medicines – including recent cell therapies Abecma and Breyanzi.
This person is not in any offices
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.